Jones Keith Anthony purchased 10,000 Humacyte shares at $0.56 per share on 2026-09-14, an open-market purchase under transaction code P. His resulting Humacyte holding was 50,000 shares, and the transaction represented about 20.0% of that holding, giving investors a precise view of the disclosed insider position.
Key Highlights
- The Humacyte transaction took place on 14 September 2026.
- Jones Keith Anthony’s resulting Humacyte holding was 50,000 shares.
- The purchase represented about 20.0% of his resulting shareholding.
Jones Keith Anthony bought 10,000 shares of Humacyte, Inc. (NASDAQ: HUMA) at $0.56 per share. The purchase was reported on 14 September 2026.
50,000-Share Resulting Position
The transaction used code P. Jones Keith Anthony’s resulting Humacyte holding stood at 50,000 shares after the transaction. The purchased block represented about 20.0% of that resulting holding. The disclosed purchase price was $0.56 per share. The filing stated that Jones Keith Anthony’s resulting position was 50,000 shares.
FAQs
Q: What did Jones Keith Anthony buy in Humacyte?
A: Jones Keith Anthony bought 10,000 Humacyte shares at $0.56 per share. The filing identified the transaction with code P and dated it 14 September 2026.
Q: What was Jones Keith Anthony’s resulting Humacyte holding?
A: Jones Keith Anthony held 50,000 Humacyte shares after the purchase. The resulting position was stated in connection with the transaction dated 14 September 2026.
Q: How much of the resulting Humacyte holding did the purchase represent?
A: The 10,000-share purchase represented about 20.0% of Jones Keith Anthony’s resulting 50,000-share Humacyte holding. The filing reported the resulting holding after the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.